Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

"Treatment-resistant depression can be very complicated ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray ... treatment is poised to change the landscape of depression management, particularly for those grappling ...

“Treatment-resistant depression can be very complicated ... symptom improvement,” the statement quoted Bill Martin of Johnson & Johnson and saying. “With Spravato now approved as a stand ...